微电生理(688351) - 2024年8月23日投资者关系活动记录表

Sales Performance - In H1 2024, the company achieved a global surgical volume of approximately 10,000 cases, generating revenue of CNY 198 million, a year-on-year increase of 39.57% [1] - Domestic revenue growth exceeded 45%, driven by product structure optimization and rapid growth of high-value iterative products [1] - International revenue increased by approximately 36%, with Q1 growth being lower due to a high base from unconventional special orders in Q1 2023 [1] Gross Margin Analysis - The overall gross margin in H1 2024 decreased compared to the same period last year, primarily due to price reductions from domestic centralized procurement and the early-stage commercialization of new products [2] - The company anticipates that production costs for new products will gradually decrease as output increases and domestic raw material substitutions are implemented [2] Product Development and Market Penetration - In H1 2024, nearly 2,000 procedures were performed using pressure radiofrequency ablation catheters in China, with one-third of these for atrial fibrillation treatment [2] - In the international market, atrial fibrillation procedures accounted for 25% of total procedures, with expectations of over 1,000 procedures for pressure catheters by the end of the year [2] Procurement and Contract Renewal - The company is actively working on contract renewals for the second year of the Fujian Alliance centralized procurement, with most provinces renewing based on the first-year contracts [2] - Specific provinces, such as Shaanxi, Guangdong, and Jiangxi, require re-evaluation for contract renewals [2] Regional Growth and Product Launches - The company experienced the fastest revenue growth in the Latin American region in H1 2024, attributed to the launch of new products, particularly pressure catheters [2] - The newly approved magnetic positioning lung catheter has shown good promotion in the market [2] R&D and Product Upgrades - The Columbus® 3D cardiac electrophysiology mapping system has been updated to its fourth generation, with ongoing upgrades focused on new consumables and AI analysis functionalities [3] - The company is engaged in various R&D projects, including pressure pulse ablation catheters and intravascular ultrasound catheters, guided by strategic considerations and industry trends [3]